Memo - Magazine of European Medical Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

CAR-T cells —Real-time experience applying CAR-T cells—What we have learned so far
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2022 Category: Cancer & Oncology Source Type: research

Molecular profiling in colorectal cancer
SummaryDespite recent advances in the management of colorectal cancer, metastatic disease remains challenging and patients are rarely cured. Chemotherapy with 5 ‑fluoruracil remains the backbone of therapy in metastatic colorectal cancer. The addition of oxaliplatin and irinotecan as well as the addition of monoclonal antibodies against vascular endothelial growth factor or in RAS wild-type tumors against the epidermal growth factor receptor improves outc ome. A better understanding of molecular pathways in cancer cells has led to the development of targeted therapies. Some of these targeted therapies show promising act...
Source: Memo - Magazine of European Medical Oncology - August 29, 2022 Category: Cancer & Oncology Source Type: research

A GLOBAL CONGRESS DIGEST ON LUNG CANCER. Report from the ASCO Hybrid Congress, 3rd – 7th June 2022
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 25, 2022 Category: Cancer & Oncology Source Type: research

Systemic inflammatory response index is a  prognostic biomarker in unresectable pancreatic adenocarcinoma and identifies patients for more intensive treatment
ConclusionOur study suggests that SIRI is able to predict OS in patients with PDAC. Patients with high SIRI values treated with platinum-based chemotherapy achieved longer OS than those treated with gemcitabine-based regimens. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 25, 2022 Category: Cancer & Oncology Source Type: research

Neoadjuvant treatment in non-small-cell lung cancer —the earlier, the better
SummaryNeoadjuvant checkpoint inhibition in resectable non-small-cell lung cancer (NSCLC) is safe and high major pathologic response (MPR) and pathologic complete response (pCR) rates can be achieved in combination with chemotherapy. The Checkmate 816 trial gives evidence that pathologic response also leads to EFS benefit. This opens new opportunities in the curative setting but also raises questions: What is the value of adjuvant treatment with checkpoint inhibitors? Or should we treat our patients peri-operatively? Which biomarkers can we use for treatment decisions and monitoring of curative patients? Targeted therapies...
Source: Memo - Magazine of European Medical Oncology - August 24, 2022 Category: Cancer & Oncology Source Type: research

CAR  T cells in multiple myeloma: Where we stand and where we might be going
SummaryIn this review we highlight the current developments in Chimeric antigen receptor (CAR) T  cell therapy for myeloma. Two advanced products (idecabtagene vicleucel and ciltacabtagene autoleucel) targeting B‑cell maturation antigen have already been approved by the US Food and Drug Administration (FDA). In heavily pretreated myeloma patients, response rates between 82 and 98% and a med ian progression-free survival between 12 and>  24 months have been achieved. Currently these two products are being investigated in earlier lines of therapy. Beside BCMA, other targets have been selected for CAR T cell ther...
Source: Memo - Magazine of European Medical Oncology - August 17, 2022 Category: Cancer & Oncology Source Type: research

Publisher Correction: Brain metastases: new systemic treatment approaches
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 17, 2022 Category: Cancer & Oncology Source Type: research

CAR  T cells in multiple myeloma: Where we stand and where we might be going
SummaryIn this review we highlight the current developments in Chimeric antigen receptor (CAR) T  cell therapy for myeloma. Two advanced products (idecabtagene vicleucel and ciltacabtagene autoleucel) targeting B‑cell maturation antigen have already been approved by the US Food and Drug Administration (FDA). In heavily pretreated myeloma patients, response rates between 82 and 98% and a med ian progression-free survival between 12 and>  24 months have been achieved. Currently these two products are being investigated in earlier lines of therapy. Beside BCMA, other targets have been selected for CAR T cell ther...
Source: Memo - Magazine of European Medical Oncology - August 17, 2022 Category: Cancer & Oncology Source Type: research

Publisher Correction: Brain metastases: new systemic treatment approaches
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 17, 2022 Category: Cancer & Oncology Source Type: research

Neoadjuvant treatment of pancreatic ductal adenocarcinoma
The objective of this report is to provide a  review of currently available study data of neoadjuvant therapy in pancreatic cancer. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 10, 2022 Category: Cancer & Oncology Source Type: research